NeuroSense Therapeutics’ (NRSN) “Buy” Rating Reiterated at D. Boral Capital

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $14.00 target price on the stock.

Several other equities analysts have also issued reports on NRSN. Roth Mkm began coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NeuroSense Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Stock Up 1.3%

Shares of NRSN stock opened at $0.82 on Tuesday. NeuroSense Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.60. The company has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $1.02.

Institutional Trading of NeuroSense Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics in the third quarter worth approximately $26,000. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics in the 2nd quarter worth about $54,000. Squarepoint Ops LLC boosted its stake in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares in the last quarter. Finally, Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.